Phase 3
Completed N=269
Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Source: ClinicalTrials.gov NCT00320528 ↗
Enrolled (actual)
269
Serious AEs
1.1%
Results posted
Jan 2010
Primary outcomePrimary: Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain — 2.65; 0.51; 3.89 T-Score
Summary
This study aims to assess the effectiveness of atomoxetine on psychosocial functioning and emotional well being of children and adolescents with ADHD and to evaluate whether and in what measure the presence of comorbid conditions (internalizing and externalizing disorders) influences atomoxetine's ability to improve the quality of life of ADHD subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain |
2.65; 0.51; 3.89 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in the Attention-Deficit/Hyperactivity Disorder (ADHD) Subscales of 18-Item Swanson, Nolan and Pelham Rating Scale (SNAP-IV) |
-5.88; -5.52; -7.58; -6.19; -5.67; -8.08 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) |
-1.23; -1.63; -1.42 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in CHIP-CE Satisfaction, Comfort, Resilience and Risk Avoidance Domains |
2.14; 0.81; 3.78; 1.01; 5.72; 4.94 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in Pediatric Anxiety Rating Scale (PARS) |
-0.18; -1.88; -1.18 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in Children's Depression Rating Scale-Revised (CDRS-R) |
-1.60; -2.56; -3.13 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in SNAP-IV Oppositional Scale |
-2.01; -2.12; -5.54 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in Adolescent Symptom Inventory-4: Parent Checklist (ASI-4) |
32.73; 38.33; 38.13; -11.4; -10.4; -11.6 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in Child Symptom Inventory-4: Parent Checklist (CSI-4) |
34.00; 36.00; 38.95; -10.6; -9.68; -12.7 | — |
| SECONDARY Change From Baseline to 12 Week Endpoint in Conners' Teacher Rating Scale-Revised: Short Form (CTRS-R:S) |
-1.42; 1.07; -2.35; -1.08; -0.47; -0.94 | — |
Eligibility Criteria
Inclusion Criteria
- Child or adolescent patients, male or female outpatients, who are at least 6 years of age, but must not yet have reached their 16th birthday prior to Visit 1, when informed consent is obtained
- Patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnostic criteria for ADHD (any subtype) and score at least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the Swanson, Nolan and Pelham Questionnaire: Attention-Deficit/Hyperactivity Disorder Subscale (SNAP-IV ADHD Subscale) score at both Visit 1 and 2
- Laboratory results, including serum chemistries, hematology, and urinalysis, must show no clinically significant abnormalities (clinically significant is defined as laboratory values requiring acute medical intervention, indicating a serious medical illness, or requiring further medical evaluation in the judgment of the investigator)
- An electrocardiogram (ECG) must be performed to exclude cardiac diseases at the baseline/screening visit and the results must be reviewed by the investigator at Visit 2 prior to dispensing of study material
- Patients and parents have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests, including venipuncture, and examinations required by the protocol.
Exclusion Criteria
- Patients who have a documented history of Bipolar I or II disorder, any history of psychosis or pervasive development disorder
- Patients with a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control are not eligible to participate
- Patients at serious suicidal risk as assessed by the investigator
- Patients with significant cardiovascular disease or other conditions that could be aggravated by an increased heart rate or increased blood pressure
- Patients who have any medical condition that would increase sympathetic nervous system activity markedly (for example, catecholamine-secreting neural tumor), or who are taking a medication on a daily basis (for example, albuterol, inhalation aerosols, pseudoephedrine), that has sympathomimetic activity. Such medications can be taken on an as-needed basis
Data sourced from ClinicalTrials.gov (NCT00320528). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.